Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization
Statistics in Medicine · 2025
DOI: 10.1002/sim.70149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Pei-Fang Su und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Research Design. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Estimating the required sample size is an essential task for a clinical trial. It ensures statistical power and makes it possible to draw meaningful conclusions from the study results. Moreover, to minimize treatment imbalances within each covariate subgroup, covariate‐adaptive randomization is a popular method. The first aim of this study is to investigate the required sample size for covariate‐adaptive randomization based on survival outcomes. We evaluate the testing performance using the calculated sample size under simple randomization, stratified permuted block randomization, and covariate‐adaptive biased coin randomization. To provide preliminary insights into the trial's progress and potential efficacy, an interim analysis is commonly conducted. The second aim of the study is to provide a strategy for interim analysis in covariate‐adaptive randomization trials, which involves stopping the trial early based on accumulating data if one treatment arm proves to be significantly more effective or harmful than the others. Because the data collected before and after the interim monitoring time are dependent, performing multiple tests may inflate the overall Type I error rate. We thus re‐estimate the required sample size, propose a valid hypothesis testing method for interim analysis, and study the underlying theoretical properties of the testing statistics, incorporating covariate‐adaptive randomization. The performance of the proposed formula and interim strategy is evaluated through comprehensive simulations, including a sensitivity analysis. We also provide the R code to benefit the readers. Finally, two survival trials, the RE01 trial and a lung cancer study, are treated as pilot studies, and we show that the proposed strategies are valid under covariate‐adaptive randomization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Statistics, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Pei-Fang Su
Förderung
- National Science and Technology Council
Zitieren
APA
Su, P. F., & Wu, C. C. (2025). Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization. Statistics in Medicine. https://doi.org/10.1002/sim.70149
Vancouver
Su PF, Wu CC. Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization. Statistics in Medicine. 2025. doi:10.1002/sim.70149
BibTeX
@article{Su2025,
author = {Su, Pei-Fang and Wu, Chieh-Chi},
title = {Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70149}
}
EUVIMED